Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High – Should You Buy?

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $4.02 and last traded at $3.95, with a volume of 11052356 shares changing hands. The stock had previously closed at $3.69.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Friday, September 19th. Wall Street Zen cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Citigroup restated a “market outperform” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Finally, Piper Sandler started coverage on shares of Esperion Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $9.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Esperion Therapeutics Trading Up 7.0%

The firm has a fifty day moving average of $2.84 and a two-hundred day moving average of $1.97. The company has a market cap of $944.29 million, a PE ratio of -7.90 and a beta of 0.92.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The business had revenue of $87.31 million for the quarter, compared to analysts’ expectations of $78.33 million. Sell-side analysts expect that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the stock. DHJJ Financial Advisors Ltd. grew its position in shares of Esperion Therapeutics by 209.2% in the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 6,380 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in Esperion Therapeutics during the 3rd quarter valued at about $29,000. R Squared Ltd bought a new stake in shares of Esperion Therapeutics during the third quarter valued at about $33,000. CWM LLC increased its position in shares of Esperion Therapeutics by 46.5% during the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 6,249 shares during the period. Finally, Meridian Wealth Management LLC purchased a new stake in shares of Esperion Therapeutics in the first quarter worth about $29,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.